Hammerman, Peter S.

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 5,461

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,789

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,580

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,200

STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment

Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 640

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 620

Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival

Rathmell, J. C., Fox, C. J., Plas, D. R., Hammerman, P. S., Cinalli, R. M., & Thompson, C. B. (2003) · Molecular and Cellular Biology

Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancer

Cited by 572

LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature

Epigenetics and DNA MethylationCancer, Hypoxia, and Metabolism

Cited by 348

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 216

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 167

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer

Deng, J., Thennavan, A., Dolgalev, I., Chen, T., Li, J., Marzio, A., Poirier, J. T., Peng, D. H., Bulatovic, M., Mukhopadhyay, S., et al. (2021) · Nature Cancer

Cancer Immunotherapy and BiomarkersAutophagy in Disease and Therapy

Cited by 140

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications

Epigenetics and DNA MethylationCancer Cells and Metastasis

Cited by 127

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 90

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., et al. (2019) · Molecular Cancer Therapeutics

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 53

Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity

Wu, D., Pang, Y., Wilkerson, M. D., Wang, D., Hammerman, P. S., & Liu, J. S. (2013) · British Journal of Cancer

Lung Cancer Research StudiesLung Cancer Treatments and Mutations

Cited by 25